A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Phase of Trial: Phase I
Latest Information Update: 17 Jun 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Mocetinostat (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors NYU Langone Medical Center
- 13 Jun 2019 Planned End Date changed from 1 Jan 2019 to 1 Dec 2019.
- 13 Jun 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Dec 2019.
- 12 Dec 2018 Planned End Date changed from 1 Oct 2018 to 1 Jan 2019.